RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) on October 8 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Day One Biopharmaceuticals (DAWN – Research ...

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve ...

IRVINE, Calif., September 18, 2024--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

Axonics, Inc. (NASDAQ:AXNX) rose 1.5% in after-hours trading after a jury voted in its favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute ...

California medical device company Axonics has won its patent infringement trial after Medtronic alleged the company had copied three elements of its sacral neuromodulation technology. The lawsuit ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ...